Prelude Therapeutics Inc 8-K

What Happened
Prelude Therapeutics Incorporated filed an 8‑K on June 10, 2026 reporting results from its June 9, 2026 Annual Meeting of Stockholders. Stockholders elected three Class III directors — Krishna Vaddi, Paul Scherer and Katina Dorton — each to three‑year terms expiring at the 2029 Annual Meeting. Stockholders also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2026 and approved (in a non‑binding vote) the 2025 compensation for the company’s named executive officers. An advisory vote on the frequency of executive compensation votes favored annual (1‑year) votes.

Key Details

• Director elections (three‑year terms to expire 2029):
  • Krishna Vaddi: For 26,996,820; Withheld 55,937; Broker non‑votes 4,799,016.
  • Paul Scherer: For 25,532,267; Withheld 1,520,490; Broker non‑votes 4,799,016.
  • Katina Dorton: For 26,998,601; Withheld 54,156; Broker non‑votes 4,799,016.
• Auditor ratified: Ernst & Young LLP — For 31,841,080; Against 4,951; Abstain 5,742; Broker non‑votes 0.
• Say‑on‑pay (advisory) for 2025 NEO compensation: For 26,869,142; Against 107,500; Abstain 76,115; Broker non‑votes 4,799,016.
• Advisory vote on pay vote frequency: 1 year 26,877,941; 2 years 65,638; 3 years 103,237; Abstain 5,941; Broker non‑votes 4,799,016.

Why It Matters
The vote results maintain board continuity with the re‑election of all three Class III directors and keep Ernst & Young as the company’s auditor, which supports continuity in financial reporting and audit oversight. The non‑binding say‑on‑pay was approved, and shareholders expressed a preference for annual advisory votes on executive compensation; while advisory, these outcomes guide company governance and investor relations. Broker non‑votes (4,799,016) reduced voting participation on several proposals, affecting the vote totals for director and advisory matters.